2015
New onset executive function difficulties at menopause: a possible role for lisdexamfetamine
Epperson CN, Shanmugan S, Kim DR, Mathews S, Czarkowski KA, Bradley J, Appleby DH, Iannelli C, Sammel MD, Brown TE. New onset executive function difficulties at menopause: a possible role for lisdexamfetamine. Psychopharmacology 2015, 232: 3091-3100. PMID: 26063677, PMCID: PMC4631394, DOI: 10.1007/s00213-015-3953-7.Peer-Reviewed Original ResearchConceptsBrown Attention-Deficit Disorder ScaleExecutive function difficultiesExecutive functionAttention Deficit Disorder ScaleLDX treatmentObjective cognitive functionMemory taskVerbal memoryVerbal recallCognitive measuresParagraph recallLifetime ADHDCognitive functionCognitive declineDisorder ScaleSubjective measuresMenopausal womenSubscale scoresLisdexamfetamineObjective measuresRecallEarly postmenopausal womenSystolic blood pressureCross-over studyHealthy menopausal women
2014
Selective Serotonin Reuptake Inhibitors and Endothelial Function in Women
Hantsoo L, Czarkowski KA, Child J, Howes C, Epperson CN. Selective Serotonin Reuptake Inhibitors and Endothelial Function in Women. Journal Of Women's Health 2014, 23: 613-618. PMID: 24886268, PMCID: PMC4089019, DOI: 10.1089/jwh.2013.4623.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBlood Flow VelocityBrachial ArteryDepression, PostpartumDepressive Disorder, MajorEndothelium, VascularFemaleFollow-Up StudiesHumansMiddle AgedNitric OxidePlatelet AggregationPremenstrual SyndromeSelective Serotonin Reuptake InhibitorsTreatment OutcomeUltrasonography, DopplerVasodilationYoung AdultConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsSSRI treatmentPremenstrual dysphoric disorderCardiovascular diseasePlatelet aggregationNO productionReuptake inhibitorsPostpartum depressionEffects of SSRIsBurden of diseasePlatelet NO productionDepression/anxietyNitric oxide functionSSRI therapyEndothelial functionVascular mechanismsVascular dilatationMajor depressionDysphoric disorderNormal rangeBeck DepressionYounger groupDiseaseWomen
2011
Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women
Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE. Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women. Menopause The Journal Of The North American Menopause Society 2011, 18: 542-548. PMID: 21293309, PMCID: PMC4076798, DOI: 10.1097/gme.0b013e3181fcafd6.Peer-Reviewed Original ResearchConceptsAttention-deficit/hyperactivity disorderBrown Attention-Deficit Disorder ScaleCognitive difficultiesHistory of ADHDBehavioral assessmentSubjective cognitive difficultiesAttention Deficit Disorder ScaleAttention/concentrationConcentration/attentionShort-term memorySimilar cognitive impairmentsCluster scoresATX treatmentExecutive functionSubjective attentionMemory difficultiesHyperactivity disorderNeuropsychological testsNeuropsychological testingCognitive symptomsDisorder ScaleSubjective difficultyAtomoxetineCognitive impairmentMemory
2010
Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch
Epperson CN, Toll B, Wu R, Amin Z, Czarkowski KA, Jatlow P, Mazure CM, O’Malley S. Exploring the impact of gender and reproductive status on outcomes in a randomized clinical trial of naltrexone augmentation of nicotine patch. Drug And Alcohol Dependence 2010, 112: 1-8. PMID: 20561758, PMCID: PMC2946976, DOI: 10.1016/j.drugalcdep.2010.04.021.Peer-Reviewed Original ResearchConceptsPlacebo groupStudy completersNaltrexone doseClinical trialsContinuous abstinenceOral naltrexone treatmentNicotine patch therapyNicotine replacement therapyInteractive voice responseRandomized clinical trialsMenstrual cycle statusEffect of doseNaltrexone augmentationNaltrexone groupAdverse eventsNaltrexone treatmentNicotine patchPatch therapyReplacement therapyQuit dayWeek 1AbstinenceDoseWomenLess adherent